Cholangiocarcinoma  >>  oxaliplatin 
Welcome,         Profile    Billing    Logout  

15 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Recruiting
3
392
RoW
TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Biliary Cancer
03/22
02/23
KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Recruiting
3
480
RoW
KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Biliary Tract Neoplasms
07/24
07/24
TOURMALINE, NCT05771480: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Recruiting
3
140
Europe, Japan, US, RoW
Durvalumab, Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union., Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Background gemcitabine-based chemotherapy Regimen
AstraZeneca
Biliary Tract Cancer
09/25
03/26
QLYY-iCCA-01, NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
25
RoW
HAIC+TAE, Tislelizumab, Surufatinib
Qilu Hospital of Shandong University, BeiGene
Intrahepatic Cholangiocarcinoma
05/24
12/25
NCT06208462: Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
33
RoW
Adebrelimab, SHR-1316, Lenvatinib, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Gemcitabine, Difluorodeoxycytidine Hydrochloride, Oxaliplatin, Diaminocyclohexane Oxalatoplatinum
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Intrahepatic Cholangiocarcinoma
01/26
01/27
CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
36
RoW
HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab
Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer
Cholangiocarcinoma Non-resectable
12/25
06/26
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
11/25
10/26
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting
2
80
Europe, US
LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo
Lisata Therapeutics, Inc.
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
12/25
12/25
KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting
2
610
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
02/27
02/27
2013-004385-34: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial

Not yet recruiting
1/2
87
Europe
Coated tablet, Powder for solution for infusion, STIVARGA, GEMCITABINE, OXALIPLATINE
Institut régional du Cancer - Montpellier - Val d'Aurelle, Institut régional du Cancer - Montpellier - Val d'Aurelle
advanced Biliary Tract Cancer, Biliary Cancer, Diseases [C] - Cancer [C04]
 
 
NCT05116891: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed
1/2
40
Europe
CAN04 (nadunolimab), nadumolimab, mFOLFOX, Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin, DTX, Docetaxel, G/C, Gemcitabine and cisplatin
Cantargia AB
Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
06/23
06/23
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
08/24
11/24
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25
PROMIFOX, NCT04729205: Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

Terminated
1b
9
RoW
Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug, Folfox
Lipomedix Pharmaceuticals Inc.
Cancer, Gastro-Intestinal Intraepithelial Neoplasia
09/23
09/23
CCGLC-007, NCT05533892: Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC

Recruiting
1
30
RoW
Nocardia rubra cell wall skeleton, N-CWS, Hepatic arterial infusion chemotherapy, HAIC, Lenvatinib, JieLiEn, Tislelizumab, BaiZeAn
Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, M&R Pharm, Geneplus-Beijing Co. Ltd., Yuce Biotechnology Co., Ltd., Geneis, Simcere Pharmaceutical Co., Ltd, BeiGene, Haplox Biotechnology Co., Ltd.
Hepatocellular Carcinoma
08/24
02/25

Download Options